A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation

Johan Törlén, Olle Ringdén, Karin Garming-Legert, Per Ljungman, Jacek Winiarski, Kari Remes, Maija Itälä-Remes, Mats Remberger, and Jonas Mattsson

Disclosures: This study was supported in part by research funding from Astellas Pharma A/S (SE-09-RG-50) and Wyeth AB/Pfizer AB (#0468x1-3329) to OR and JM. Johan Törlén (JT): None. Olle Ringdén (OR): None to declare, except the research funding stated at the top. Karin Garmin-Legert (KGL): Congress fee to the EBMT 2016 was sponsored by Camurus. Per Ljungman (PL): See file in the ASCO Disclosure Management System. Jacek Winiarski (JW): None. Kari Remes (KR): Have been a member for advisory boards and got payment from the companies Amgen, Janssen-Cilag, Takeda and Teva. Research grant from Amgen, and travel, accommodation and expenses regarding congress trips have been reimbursed to KR's institution from Amgen, Celgene, Janssen-Cilag and Takeda. Maija Itälä-Remes (MIR): Have been a member for advisory boards of Amgen, Janssen-Cilag, ARIAD and Teva. Congresses have been reimbursed to MIR's institution from Amgen, Celgene, Janssen-Cilag and ARIAD. Mats Remberger (MR): None. Jonas Mattsson (JM): Supported by grants from the Swedish Cancer Society (CF 2014-2016), the Swedish Children's Cancer Foundation (PR2013-0022 and KF2013-0011), the Marianne and Marcus Wallenberg Foundation (2013.0117), and by grants provided by Stockholm County Council (ALF Project, 20140451).

Contributions: OR, JM, and MR designed the study; JT, OR, KGL, PL, KGL, JW and JM were responsible for patient accrual and care in Sweden; KR and MIR were responsible for patient accrual and care in Finland; JT and MR collected the data and performed the data management and analyses, and MR performed the statistical analyses. JT, MR and JM drafted the manuscript and OR, KGL, PL, JW, KR, and MIR reviewed and approved the manuscript.